I didn't know my medication made me more sensitive to the sun
I had never before considered that my prescription could influence the way my body copes in high temperatures.But, according to Dr Cave, "there are many medicines that can increase your sensitivity to heat and sunlight".
Prescriptions range from diuretics and blood pressure medications to antidepressants and antipsychotics. Certain drugs can increase the skin's sensitivity to the sun, suppress thirst and reduce your ability to sweat. Some, like the stimulants I take, raise your body temperature, making you more vulnerable to overheating. "We also see a number of commonly prescribed medications - including some antibiotics, antidepressants, acne treatments, and painkillers like ibuprofen - that can increase your skin's sensitivity to the sun," Dr Cave added. For me, the warning of this possibility had been there all along, in the informational leaflet that comes along with my prescription. But I didn't properly read that advice until I returned home from the holiday, wondering whether my meds were the reason I had been so sick.Dr Cave recommended that you should "always read the patient information leaflet, and don't hesitate to ask your pharmacist or healthcare provider for guidance", if taking medication when the weather is warmer.
Emergency departments across the UK have recently reported a surge in people seeking urgent care during the August heatwave. The signs of heat exhaustion can include dizziness, headaches, excessive sweating, fatigue, nausea and muscle cramps. Left unchecked it can progress to heatstroke, a medical emergency that can be life-threatening.Looking back, my symptoms make perfect sense. The sun was unrelenting in Rhodes, reaching temperatures up to the mid-30s.Not knowing that I was at a heightened risk, I was drinking far less water than I should have, and sitting in direct sunlight at the hottest time of day, hoping to get a tan.
If someone is experiencing the symptoms of heat stroke, the NHS recommends moving them to a cool place, removing unnecessary layers, getting them to drink something hydrating, and cooling their skin.If they do not feel better after 30 minutes or have any other symptoms of heatstroke, you should call 999. Dr Cave said if you are taking medication and the weather turns warmer, the MHRA's advice is clear: "Stay hydrated, stay informed, and take sensible precautions."This includes ensuring medication is stored in a cool, dry place and out of direct sunlight. She also stressed the importance of reporting any side effects related to heat or sunlight while taking medication via the Yellow Card scheme, and not stopping medication without speaking to a doctor first.
Overall, I returned from my holiday with more than just a sun tan. I came home with a new-found understanding of the impact my medication can have on my body, and a reminder to thoroughly read through the leaflets that come along with any medication I take.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
an hour ago
- The Independent
Drug that slows onset of type 1 diabetes licensed for use in UK-first
A groundbreaking drug that slows down the development of type 1 diabetes has been licensed for use in the UK. Teplizumab can allow patients to live 'normal lives' without the need for insulin injections. Experts hailed the decision by the Medicines and Healthcare Regulatory Agency (MHRA) as a 'breakthrough moment' that represents a 'turning point' in how the condition is treated. About 400,000 people in the UK have type 1 diabetes, a lifelong condition which causes the immune system to attack insulin-producing cells in the pancreas. Insulin helps the body use sugar for energy, and without this hormone, blood sugar levels can become dangerously high. Type 1 diabetes needs constant management to keep blood sugar within range, with patients required to take insulin through injections or pumps. Teplizumab trains the immune system to stop attacking pancreatic cells. It is taken by an IV drip for a minimum of 30 minutes over 14 consecutive days. The drug, which is already approved in the US, has been authorised for use by the MHRA to delay the onset of stage three type 1 diabetes in adults and children aged eight or over by an average of three years. Ahmed Moussa, general manager of general medicines UK and Ireland at Sanofi, which makes teplizumab, said: 'One hundred years ago the discovery of insulin revolutionised diabetes care. Today's news marks a big step forward.' The UK is the first country in Europe to be granted a licence. Type 1 diabetes develops gradually in three stages over months or years. Stage three is usually when people start to experience blood sugar problems and are diagnosed with the condition. According to the MHRA, teplizumab is used in people with stage two type 1 diabetes, which is an earlier stage of the disease during which patients are at a high risk of progressing to stage three. Parth Narendran, a professor of diabetes medicine at the University of Birmingham and The Queen Elizabeth Hospital Birmingham, said: 'Teplizumab essentially trains the immune system to stop attacking the beta cells in the pancreas, allowing the pancreas to produce insulin without interference. 'This can allow eligible patients to live normal lives, delaying the need for insulin injections and the full weight of the disease's daily management by up to three years. It allows people to prepare for disease progression rather than facing an abrupt emergency presentation.' Following the decision by the MHRA, the cost-effectiveness of teplizumab will be assessed by NHS spending watchdog the National Institute for Health and Care Excellence (Nice) to determine if it can be rolled out on the health service. Karen Addington, chief executive of the charity Breakthrough T1D, said: 'I am personally delighted and welcome the MHRA's approval of teplizumab. 'After years of research, clinical trials and drug development, we have an incredible breakthrough.' Reacting to the announcement, Dr Elizabeth Robertson, director of research and clinical at Diabetes UK, said: 'Today's landmark licensing of teplizumab in the UK marks a turning point in the treatment of type 1 diabetes. 'For the first time, we have a medicine that targets the root cause of the condition, offering three precious extra years free from the relentless demands of managing type 1 diabetes.' Dr Robertson added that the 'next steps are critical'. 'To ensure teplizumab reaches everyone who could benefit, we need it to be made available on the NHS, and the rollout of a screening programme to identify those with early-stage type 1 diabetes,' she said.
Western Telegraph
2 hours ago
- Western Telegraph
Drug that slows onset of type 1 diabetes licensed for use in UK-first
Teplizumab can allow patients to live 'normal lives' without the need for insulin injections. Experts hailed the decision by the Medicines and Healthcare Regulatory Agency (MHRA) as a 'breakthrough moment' that represents a 'turning point' in how the condition is treated. One hundred years ago the discovery of insulin revolutionised diabetes care. Today's news marks a big step forward Ahmed Moussa, Sanofi About 400,000 people in the UK have type 1 diabetes, a lifelong condition which causes the immune system to attack insulin-producing cells in the pancreas. Insulin helps the body use sugar for energy, and without this hormone, blood sugar levels can become dangerously high. Type 1 diabetes needs constant management to keep blood sugar within range, with patients required to take insulin through injections or pumps. Teplizumab trains the immune system to stop attacking pancreatic cells. It is taken by an IV drip for a minimum of 30 minutes over 14 consecutive days. The drug, which is already approved in the US, has been authorised for use by the MHRA to delay the onset of stage three type 1 diabetes in adults and children aged eight or over by an average of three years. Ahmed Moussa, general manager of general medicines UK and Ireland at Sanofi, which makes teplizumab, said: 'One hundred years ago the discovery of insulin revolutionised diabetes care. Today's news marks a big step forward.' The UK is the first country in Europe to be granted a licence. Type 1 diabetes develops gradually in three stages over months or years. Stage three is usually when people start to experience blood sugar problems and are diagnosed with the condition. According to the MHRA, teplizumab is used in people with stage two type 1 diabetes, which is an earlier stage of the disease during which patients are at a high risk of progressing to stage three. Parth Narendran, a professor of diabetes medicine at the University of Birmingham and The Queen Elizabeth Hospital Birmingham, said: 'Teplizumab essentially trains the immune system to stop attacking the beta cells in the pancreas, allowing the pancreas to produce insulin without interference. 'This can allow eligible patients to live normal lives, delaying the need for insulin injections and the full weight of the disease's daily management by up to three years. It allows people to prepare for disease progression rather than facing an abrupt emergency presentation.' Following the decision by the MHRA, the cost-effectiveness of teplizumab will be assessed by NHS spending watchdog the National Institute for Health and Care Excellence (Nice) to determine if it can be rolled out on the health service. After years of research, clinical trials and drug development, we have an incredible breakthrough Karen Addington, Breakthrough T1D Karen Addington, chief executive of the charity Breakthrough T1D, said: 'I am personally delighted and welcome the MHRA's approval of teplizumab. 'After years of research, clinical trials and drug development, we have an incredible breakthrough.' Reacting to the announcement, Dr Elizabeth Robertson, director of research and clinical at Diabetes UK, said: 'Today's landmark licensing of teplizumab in the UK marks a turning point in the treatment of type 1 diabetes. 'For the first time, we have a medicine that targets the root cause of the condition, offering three precious extra years free from the relentless demands of managing type 1 diabetes.' Dr Robertson added that the 'next steps are critical'. 'To ensure teplizumab reaches everyone who could benefit, we need it to be made available on the NHS, and the rollout of a screening programme to identify those with early-stage type 1 diabetes,' she said.
Daily Mail
2 hours ago
- Daily Mail
The secret to living longer may be the immune system's 'fountain of youth' - but it comes at a price
If you want to reach your 100th birthday and receive a telegram from the King, the answer may be in your immune system. For some over 60s with 'immune youth' have specialised white blood cells that restore strength and muscle mass, scientists have discovered. According to US researchers, who tracked more than 100 older adults, these cells known as Stem-like T cells, give people younger immune systems. But they also discovered those with the cells, also called stem-like memory T cells or TSL, could spread disease more easily. Instead, those with such cells were more likely to have autoimmunity—when the immune system mistakenly attacks healthy tissues and organs instead of defending it. Dr Cornelia Weyand, a rheumatologist, expert in immune cell function at the Mayo Clinic in Minnesota and study co-author, said: 'We observed that these patients have very young immune systems despite being in their 60s and 70s. 'But the price they pay for that is autoimmunity.' Dr Jörg Goronzy, an immunologist at the Mayo Clinic and study co-author, added: 'Contrary to what one may think, there are benefits to having an immune system that ages in tandem with the body. 'We need to consider the price to pay for immune youthfulness. That price can be autoimmune disease.' In the study, researchers tracked the 100 over 60s who attended the Mayo Clinic to receive treatment for giant cell arteritis, an autoimmune disease that affects the arteries, including the aorta. Writing in the journal Nature Aging, they said they found stem-like T cells in the diseased tissue of these patients. They also discovered the immune checkpoint inhibitors that regulate the immune system were not working properly. The scientists said they are now in the process of developing new diagnostic tests that will help find patients and healthy individuals who carry high numbers of immune stem cells and may be predisposed to autoimmune disease later in life. Last year, research suggested life expectancy across the world will rise by almost five years by 2050, with the average man forecasted to live to 76 and woman, past 80. Global average life expectancy is forecast to increase to around 78.1 years of age in 2050, a rise of 4.5 years, The Lancet Public Health study also found. At the time, experts said the trend was largely driven by public health measures both preventing and improving survival rates from illnesses including cardiovascular disease, nutritional diseases and maternal and neonatal infections. Commentators also said the figures present an 'immense opportunity' to 'get ahead of rising metabolic and dietary risk factors' such as high blood pressure and BMI. The oldest living person in the world is now believed to be Ethel Caterham, from Surrey, who was born on August 21, 1909 and is 115 years old. The title of the oldest person to have ever lived belongs to French woman Jeanne Louise Calment whose life spanned 122 years and 164 days. Ms Caterham, who died in 1997, attributed her longevity to 'never arguing with anyone, I listen and I do what I like'. Experts who have studied centenarians agree. Physical activity, faith, love, companionship, and a sense of purpose make up the backbone of so-called 'Blue Zones,' or areas of the world where people typically live to 100 and beyond. Maintaining an active lifestyle, even simply walking around town every day, has been shown to improve longevity. Companionship has been shown to have a similarly positive effect on a person's lifespan, with studies consistently showing loneliness is toxic.
